PARIS--(BUSINESS WIRE)--Regulatory News:
BioAlliance Pharma SA (Paris:BIO)(Euronext Paris - BIO), a company dedicated to specialty and orphan oncology products, today announces two key steps in the development of its AMEP™ biotherapy with the submission to the French drug agency (Afssaps) of a phase I/II clinical trial in the metastatic melanoma and the grant of a European patent covering the product until 2022.
BioAlliance Pharma SA (Paris:BIO)(Euronext Paris - BIO), a company dedicated to specialty and orphan oncology products, today announces two key steps in the development of its AMEP™ biotherapy with the submission to the French drug agency (Afssaps) of a phase I/II clinical trial in the metastatic melanoma and the grant of a European patent covering the product until 2022.
